Business Context and Reporting Period
This Form 8-K is filed by Athira Pharma, Inc. (not Leonabio, Inc.) on October 18, 2021. The company is a clinical-stage biotechnology firm developing ATH-1017, a small molecule prodrug for dementia associated with Alzheimer's and Parkinson's diseases. The filing reports the completion of an internal investigation into allegations of research misconduct by former CEO Dr. Leen Kawas and subsequent leadership changes.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and separation terms:
- Dr. Mark Litton (New CEO): Annual base salary increased to $510,000 (retroactive to Oct 1, 2021); target cash incentive of 40% of base; 60,000 RSUs with milestone-based vesting.
- Ms. Rachel Lenington (New COO): Annual base salary increased to $430,000 (retroactive to Oct 1, 2021); target cash incentive of 40% of base; 150,000 stock options and 30,000 RSUs.
- Dr. Hans Moebius (CMO): Annual base salary increased to $430,000.
- Ms. Glenna Mileson (CFO): Annual base salary increased to $405,000.
- Dr. Leen Kawas (Former CEO): Separation package includes a lump sum of $510,000 (one year base salary) and COBRA coverage for up to 18 months.
Material Changes
The primary material change is the resignation of Dr. Leen Kawas as President, CEO, and Board member, effective October 18, 2021. Concurrently, Dr. Mark Litton was appointed President and CEO, and Ms. Rachel Lenington was appointed COO. These changes follow a special committee investigation which found that Dr. Kawas altered images in her 2011 doctoral dissertation and at least four research papers co-authored between 2011 and 2014.
Outlook, Risks, and Contingencies
Investigation Findings: The special committee found that Athira's issued U.S. patent for ATH-1017 does not cite any paper containing altered images. However, the committee noted that the Washington State University (WSU) patent for dihexa (the active metabolite of ATH-1017) incorporates images from papers co-authored by Dr. Kawas that were altered. WSU is conducting its own ongoing investigation into potential misconduct.
Risks: Athira cannot predict the outcome or timeline of the WSU investigation. While the company has conducted alternative preclinical studies to support ATH-1017's activity, the potential impact of the WSU findings on the dihexa patent and related intellectual property remains a contingency.
Compensation Risks: New executive agreements include change-in-control provisions offering lump-sum payments (9 to 12 months of salary) and accelerated equity vesting if terminated without cause or for good reason during a change-in-control period.
Investor Verification Checklist
- Verify the status and potential outcome of the Washington State University investigation into Dr. Kawas's research.
- Confirm the validity and enforceability of the dihexa patent licensed from WSU given the findings of image alteration.
- Review the specific clinical development milestones required for the vesting of Dr. Litton's and Ms. Lenington's RSU awards.
- Assess the impact of the leadership transition on the ongoing Phase 1a/b clinical trial and future development of ATH-1017.